Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Guardant Health Inc (GH)

Guardant Health Inc (GH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,589,246
  • Shares Outstanding, K 126,041
  • Annual Sales, $ 739,020 K
  • Annual Income, $ -436,370 K
  • EBIT $ -442 M
  • EBITDA $ -404 M
  • 60-Month Beta 1.58
  • Price/Sales 15.92
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 59.11% (-0.37%)
  • Historical Volatility 36.46%
  • IV Percentile 33%
  • IV Rank 20.77%
  • IV High 103.43% on 04/04/25
  • IV Low 47.50% on 08/13/25
  • Expected Move (DTE 29) 13.29 (11.33%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 2,283
  • Volume Avg (30-Day) 1,272
  • Put/Call OI Ratio 0.95
  • Today's Open Interest 14,795
  • Open Int (30-Day) 37,646
  • Expected Range 103.99 to 130.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.81
  • Number of Estimates 4
  • High Estimate -0.76
  • Low Estimate -0.86
  • Prior Year -0.90
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
97.31 +20.52%
on 01/05/26
120.74 -2.87%
on 01/22/26
+15.94 (+15.73%)
since 12/22/25
3-Month
66.59 +76.12%
on 10/23/25
120.74 -2.87%
on 01/22/26
+49.25 (+72.39%)
since 10/22/25
52-Week
34.88 +236.24%
on 03/10/25
120.74 -2.87%
on 01/22/26
+70.08 (+148.47%)
since 01/22/25

Most Recent Stories

More News
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

First FDA-approved CDx for Guardant360 CDx in colorectal cancer further expands its role in guiding targeted therapy across solid tumors Approval supported...

GH : 117.28 (+1.32%)
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

Multi-year global collaboration will utilize Guardant liquid biopsy portfolio for the development of companion diagnostics for drug approvals

GH : 117.28 (+1.32%)
Guardant Health (NASDAQ:GH): Strongest Q3 Results from the Testing & Diagnostics Services Group

Guardant Health (NASDAQ:GH): Strongest Q3 Results from the Testing & Diagnostics Services Group

GH : 117.28 (+1.32%)
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results

Fourth quarter revenue growth of 39% driven by strong Oncology and Screening volume

GH : 117.28 (+1.32%)
Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families

Active-duty service members and eligible family members now have access to blood test for colorectal cancer screening with no copay

GH : 117.28 (+1.32%)
1 Growth Stock Set to Flourishand 2 We Avoid

1 Growth Stock Set to Flourishand 2 We Avoid

GH : 117.28 (+1.32%)
CDNS : 317.09 (+1.04%)
WD : 65.13 (+1.54%)
Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 44 th Annual J.P. Morgan Healthcare Conference in San...

GH : 117.28 (+1.32%)
Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

Partnership integrates Guardant’s large-scale genomic data with Trial Library’s AI-powered matching and navigation platform to expand equitable access to oncology clinical trials across the United...

GH : 117.28 (+1.32%)
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy

Leading European Hospital System Begins Offering On-site Liquid Biopsy Testing Based on Proprietary Guardant360® CDx Technology

GH : 117.28 (+1.32%)
3 Volatile Stocks Walking a Fine Line

3 Volatile Stocks Walking a Fine Line

GH : 117.28 (+1.32%)
NMRK : 17.57 (-1.01%)
FND : 75.89 (+1.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption,...

See More

Key Turning Points

3rd Resistance Point 124.82
2nd Resistance Point 122.78
1st Resistance Point 120.03
Last Price 117.28
1st Support Level 115.24
2nd Support Level 113.20
3rd Support Level 110.45

See More

52-Week High 120.74
Last Price 117.28
Fibonacci 61.8% 87.94
Fibonacci 50% 77.81
Fibonacci 38.2% 67.68
52-Week Low 34.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar